Matrix Capital, SoftBank, Fidelity led the $525m Series C round in ElevateBio.

Investment firms Matrix Capital, SoftBank Vision Fund 2 and Fidelity led the $525m Series C round in ElevateBio, a cell and gene therapy technology company. Existing investors MPM Capital, F2 Ventures, Redmile Group, EcoR1 Capital, Samsara BioCapital, The Invus Group, Emerson Collective, Surveyor Capital, EDBI, Vertex Ventures, and iTochu participated in the round. “While we see remarkable breakthroughs in the earliest days of the cell and gene therapy revolution, accelerating innovation requires next-generation technology, analytics, and production capabilities to deliver therapies better, faster, and cheaper. We are poised to power the field today and for many decades to come and are thrilled to welcome Matrix Capital Management, SoftBank, and Fidelity to our stellar group of existing investors," David Hallal, ElevateBio Chairman and Chief Executive Officer